Clinical Research Directory

Inclusion Criteria: 1. Aged 18 or older. 2. Has provided written Informed Consent for participation in this trial and is willing to comply with the study. 3. Patients undergoing external beam radiotherapy. 4. Histologically proven Stage I NSCLC or oligometastatic lung metastases (3 or less). 5. Diagnostic CT prior to insertion of fiducial markers. 6. Patient must be able to have fiducial markers placed in the lung (if on anticoagulants, must be cleared by LMO or cardiologist). 7. ECOG performance status 0-2. 8. A maximum of three metastases to the lung from any non-haematological malignancy. Multiple metastases will be treated separately. 9. 1 cm ≤ Tumour diameter in any dimension ≤ = 5 cm. 10. The distance between the tumour centroid and the top end of the diaphragm is \<=8 cm. Exclusion Criteria: 1. Patient has low respiratory performance as evaluated by the physicians. 2. Previous high-dose thoracic radiotherapy. 3. Less than one fiducial marker implanted in the lung. 4. Fiducial markers are too far from the tumour centroid (\>9 cm). 5. Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Hormonal manipulation agents are allowable (e.g. aromatase inhibitors, selective oestrogen receptor modulators, and gonadotropin releasing hormone receptor modulators). 6. Targeted agents (such as sunitinib, bevacizumab and tarceva) within 7 days of commencement of treatment, concurrently with treatment or 7 days after radiotherapy. 7. Women who are pregnant or lactating. 8. Unwilling or unable to give informed consent. 9. Unwilling or unable to complete quality of life questionnaires.